University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine Hematology and Medical Oncology

Topics

• HER2/EGFR in Cancer Research 108
• Acute Myeloid Leukemia Research 104
• Multiple Myeloma Research and Treatments 92
• PI3K/AKT/mTOR signaling in cancer 67
• Myeloproliferative Neoplasms: Diagnosis and Treatment 63
• Advanced Breast Cancer Therapies 58
• DNA Repair Mechanisms 57
• TGF-β signaling in diseases 57
• Lung Cancer Treatments and Mutations 38
• Cancer Immunotherapy and Biomarkers 36
• Cancer Treatment and Pharmacology 33
• CAR-T cell therapy research 33

Most cited

1. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.

   Lancet (London, England) · 2024 · 686 citations · Montaser Shaheen

2. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

   The New England journal of medicine · 2023 · 739 citations · Montaser Shaheen

3. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

   The New England journal of medicine · 2022 · 671 citations · Carlos Arteaga

4. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 629 citations · Virginia Kaklamani

5. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.

   JAMA oncology · 2023 · 399 citations · Andrew Brenner

6. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.